Soleus Capital Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802630

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2025 · 88 positions · Total reported value $1.99B · Top-10 concentration 48.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 72.6% · 27 new · 36 cut · 27 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -6.9% · vs SPY -9.0% · Prev Value $2.90B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.4% · vs SPY -3.6% · Latest Value $2.81B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2025 13F filing, Soleus Capital Management, L.P. disclosed 88 equity positions with a combined reported value of $1.99B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 48.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were KRYS ($179.85M), TGTX ($138.89M), NVCR ($124.61M). By sector, the heaviest allocations are Health Care 84.3%, Other 15.7%. Versus the prior quarter, allocation shifted toward Other (+2.7pp) and away from Health Care (-2.7pp).

Versus the prior quarter, Soleus Capital Management, L.P. opened 27 new positions, trimmed 36 and fully exited 27, a turnover rate of 72.6% of positions. The portfolio's overlap with the prior quarter was 62% of names.

The largest new positions opened in Q3 2025 were FOLD ($36.96M), INDV ($35.35M), NBIX ($19.37M).

Of the 27 positions fully exited versus the prior quarter, the largest were UNH ($26.91M), SRDX ($23.44M), HUM ($19.46M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • FOLD AMICUS THERAPEUTIC · $36.96M
  • INDV INDIVIOR PHARMACEUTICALS INC · $35.35M
  • NBIX NEUROCRINE BIOSCIENCES INC · $19.37M
  • BLTE BELITE BIO INC · $15.54M
  • RAPT RAPT THERAPEUTICS INC · $13.87M
  • QURE UNIQURE NV · $11.67M
  • GMED GLOBUS MED INC · $10.08M
  • GSK GSK PLC · $9.50M

Fully Exited (vs previous quarter)

  • UNH UNITEDHEALTH GROUP INC · prev qtr: $26.91M
  • SRDX SURMODICS INC · prev qtr: $23.44M
  • HUM HUMANA INC · prev qtr: $19.46M
  • ASND ASCENDIS PHARMA A/S · prev qtr: $14.67M
  • THTX THERATECHNOLOGIES INC · prev qtr: $11.33M
  • ENOV ENOVIS CORPORATION · prev qtr: $9.88M
  • SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $4.43M
  • TNDM TANDEM DIABETES CARE INC · prev qtr: $3.73M

Insider Transactions (Form 4)

Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-11 Conversion Parabilis Medicines, Inc. 527,070 $9.48 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 125,000 $20.00 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 375,000 $20.00 SEC filing

All insider transactions →

Fund Profile

Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 97 US equity positions with a combined value of $2.81B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-118942 (status: Approved), registered 2020-06-25
  • Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 1 hedge funds

Portfolio Structure

  • 97 positions · $2.81B reported value (Q3 2026)
  • Top 10 holdings = 53.0% of reported value
  • Largest position: KRYS (KRYSTAL BIOTECH INC) at 13.5%
  • Average position size: $29.00M

Sector Tilt

  • Health Care 98.6%
  • Information Technology 0.0%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 27 new, 28 added, 36 reduced, 27 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 84.3%
Other 15.7%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.02M $179.85M 9.05%
9.05%
Add
2 3.84M $138.89M 6.99%
6.99%
Add
3 9.64M $124.61M 6.27%
6.27%
Add
4 1.15M $115.23M 5.80%
5.80%
Add
5 259.65K $83.90M 4.22%
4.22%
Add
6 3.87M $76.90M 3.87%
3.87%
Add
7 150.00K $62.88M 3.17%
3.17%
Reduce
8 8.13M $61.03M 3.07%
3.07%
Hold
9 1.18M $58.24M 2.93%
2.93%
Reduce
10 728.19K $54.03M 2.72%
2.72%
Add
11 1.87M $52.52M 2.64%
2.64%
Add
12 69.43K $51.21M 2.58%
2.58%
Add
13 12.13M $51.20M 2.58%
2.58%
Reduce
14 890.30K $48.22M 2.43%
2.43%
Reduce
15 493.81K $47.29M 2.38%
2.38%
Add
16 859.17K $45.54M 2.29%
2.29%
Reduce
17 4.69M $36.96M 1.86%
1.86%
New
18 1.47M $35.35M 1.78%
1.78%
New
19 68.34K $31.34M 1.58%
1.58%
Add
20 340.24K $31.17M 1.57%
1.57%
Add
21 2.01M $30.96M 1.56%
1.56%
Add
22 1.73M $30.80M 1.55%
1.55%
Add
23 2.96M $30.50M 1.53%
1.53%
Add
24 2.50M $24.90M 1.25%
1.25%
Reduce
25 17.29M $23.69M 1.19%
1.19%
Add
26 2.42M $22.39M 1.13%
1.13%
Hold
27 1.44M $20.65M 1.04%
1.04%
Add
28 138.00K $19.37M 0.97%
0.97%
New
29 626.04K $19.17M 0.96%
0.96%
Add
30 7.31M $16.74M 0.84%
0.84%
Hold
31 647.05K $16.14M 0.81%
0.81%
Reduce
32 497.95K $15.67M 0.79%
0.79%
Add
33 7.05M $15.66M 0.79%
0.79%
Add
34 210.00K $15.54M 0.78%
0.78%
New
35 422.06K $14.49M 0.73%
0.73%
Reduce
36 537.90K $13.87M 0.70%
0.70%
New
37 679.00K $13.55M 0.68%
0.68%
Reduce
38 500.00K $13.44M 0.68%
0.68%
Reduce
39 413.50K $12.16M 0.61%
0.61%
Add
40 290.00K $11.68M 0.59%
0.59%
Add
41 200.00K $11.67M 0.59%
0.59%
New
42 375.00K $11.04M 0.56%
0.56%
Add
43 148.70K $10.90M 0.55%
0.55%
Reduce
44 738.00K $10.82M 0.55%
0.55%
Add
45 6.33M $10.25M 0.52%
0.52%
Hold
46 176.00K $10.08M 0.51%
0.51%
New
47 220.00K $9.50M 0.48%
0.48%
New
48 330.01K $9.35M 0.47%
0.47%
Reduce
49 1.45M $8.90M 0.45%
0.45%
Reduce
50 935.91K $8.26M 0.42%
0.42%
Hold

FAQ

What did Soleus Capital Management, L.P. buy in 2025-Q3?

In its 2025-Q3 13F filing, Soleus Capital Management, L.P. reported 88 equity positions worth $1.99B in aggregate; its largest disclosed positions were KRYS ($179.85M), TGTX ($138.89M), NVCR ($124.61M).

How large is Soleus Capital Management, L.P.'s portfolio?

Soleus Capital Management, L.P. reported $1.99B of long equity holdings across 88 positions as of 2025-Q3. Top-10 holdings account for 48.1% of reported value.

What is Soleus Capital Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/soleus-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →